Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

Research output: Contribution to journalArticlepeer-review


  • Gianluca Ianiro
  • Benjamin H Mullish
  • Colleen R Kelly
  • Zain Kassam
  • Ed J Kuijper
  • Siew C Ng
  • Jessica R Allegretti
  • Stefano Bibbò
  • Harry Sokol
  • Faming Zhang
  • Monika Fischer
  • Samuel Paul Costello
  • Josbert J Keller
  • Luca Masucci
  • Joffrey van Prehn
  • Gianluca Quaranta
  • Jonathan Segal
  • Dina Kao
  • Reetta Satokari
  • Maurizio Sanguinetti
  • Herbert Tilg
  • Antonio Gasbarrini
  • Giovanni Cammarota

External organisations

  • Center for Digestive Disease, Division of Coloproctology, Karolinska University Hospital, Stockholm, Sweden.
  • Imperial College London
  • The Warren Alpert Medical School of Brown University
  • Finch Therapeutics Group
  • Leiden University
  • University Hospitals Birmingham NHS Foundation Trust
  • Harvard Medical School
  • INRA Avignon
  • the Second Affiliated Hospital of Nanjing Medical University
  • Riley Children's Hospital, Indiana University, Indianapolis, Indiana, USA.
  • University of Adelaide
  • Department of Medicine, Gastroenterology Division, McMaster University
  • Institute for Microbiology and Infection
  • Alberta Glycomics Centre, University of Alberta, Alberta, Canada
  • University of Helsinki and Helsinki University Hospital, Helsinki 00290
  • Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria.
  • The Chinese University of Hong Kong


The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of Clostridioides difficile infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities.

Bibliographic note

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.


Original languageEnglish
Publication statusE-pub ahead of print - 3 Jul 2020